Novo Nordisk and AWS Launch AI Drug Discovery Hub to Accelerate Medicine Development

Novo Nordisk teams with Amazon Web Services to launch a joint AI‑driven drug discovery hub designed to speed early‑stage molecule design, screening, and optimization across its research pipeline while integrating advanced AI algorithms.

AWS will supply the cloud computing power, machine‑learning platforms, and data‑analytics tools needed for Novo Nordisk scientists to run large‑scale simulations, predictive modeling, and data‑intensive experiments within the new hub environment.

AI Drug Discovery Market report, the third edition released in 2026, outlines industry trends and provides a forecast through 2035, highlighting growing investment in AI platforms and collaborative research hubs as primary growth drivers.

Industry analysts project that the Novo Nordisk‑AWS hub will significantly shorten drug candidate identification cycles, lower development costs, and enable faster delivery of novel therapies to patients compared with traditional discovery approaches.